Gambro takes over renal care products sales in Brazil

Gambro takes over renal care products sales in Brazil Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, has effective September 10, 1999 taken over the sales rights for renal intensive care products in Brazil from Urbitech, which has been a sales agent in these markets. The sales rights represent annual sales of about SEK 10 million. The transaction is part of the strategic restructuring program within the Renal Care Products business area and will substantially strengthen Gambro's market position on the Brazilian market. As part of the strategy to consolidate Gambro's sales operation, similar moves have been taken in the Nordic area and in Korea during 1999. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 33 Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 42,000 patients in 565 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/09/28/19990928BIT00280/bit0001.doc http://www.bit.se/bitonline/1999/09/28/19990928BIT00280/bit0002.pdf

About Us

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.

Subscribe